- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
AlphaRx, a leader in the development of Nanotechnology for Drug Delivery Platforms, is pleased to announce that it has received conditional approval from the TSX Venture Exchange to list the common shares of the Company on the Exchange. Listing of the common shares on the TSX Venture Exchange is subject to compliance with all conditions of the Exchange, including receipt of all required documentation. AlphaRx intends to fulfill the listing conditions as soon as is practical.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.
For more information, please click here
AGORACOM Investor Relations Corp.
Copyright © AlphaRx, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016